Merck’s Roger Dansey Joins Seattle Genetics as Chief Medical Officer

Xconomy Seattle — 

Roger Dansey has been appointed chief medical officer of Seattle Genetics (NASDAQ: SGEN). Dansey comes to Bothell, WA-based SeaGen from Merck (NYSE: MRK), where he was a senior vice president in oncology. Dansey succeeds Jonathan Drachman, who will continue working with SeaGen as a strategic advisor. SeaGen develops and sells cancer therapies based on its antibody-drug conjugate technology.